ScottTylerAaronsonMD

Adjunct Professor, Psychiatry, University of Maryland School of Medicine Chief Science Officer, Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt Health System

Join to view full profile

Dr. Aaronson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Aaronson's full profile

Already have an account?

Office
6501 N Charles St
Towson, MD 21204
Phone+1 410-938-3125

Fax+1 410-938-3111

Summary

Dr. Scott Aaronson is a psychiatrist in Towson, MD and is affiliated with Sheppard Pratt Health System. He received his medical degree from Harvard Medical School and has been in practice 36 years. His research covers novel treatments for difficult to treat mood and anxiety disorders and includes multiple studies with psychedelics as well as experimental neuromodulation techniques. He has more than 100 publications and over 3000 citings.

Education & Training

Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1981 - 1985
Harvard Medical SchoolClass of 1981

Certifications & Licensure

MD State Medical License 2001 - 2026
MA State Medical License 1982 - 2001
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Treatment-Resistant Depression Registry Start of enrollment: 2006 Jan 01
Completed
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1) Start of enrollment: 2011 Sep 01
Terminated
Not Applicable
Investigating tDCS as a Treatment for Unipolar and Bipolar Depression Start of enrollment: 2012 Jun 01
Completed
Phase 2, Phase 3
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Start of enrollment: 2013 Oct 01
Completed
Phase 2
Schizophrenia Cognition Scale Development Start of enrollment: 2013 Nov 01
Completed
Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia Start of enrollment: 2014 Sep 01
Terminated
Phase 2
Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents Start of enrollment: 2015 Oct 01
Unknown status
Not Applicable
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease Start of enrollment: 2016 Jun 01
Terminated
Phase 3
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. Start of enrollment: 2021 Mar 01
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.
Sara Ellis, Catherine Bostian, Wendy Feng, Eileen Fischer, Garrett Schwartz
Journal of Affective Disorders. 2025-01-15
Update on the assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form-2 (ATHF-SF2).
Harold A Sackeim, Scott T Aaronson, Mark T Bunker, Charles R Conway, Mark S George
Journal of Psychiatric Research. 2024-08-01
Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety-Reply.
Scott T Aaronson, Andrew van der Vaart, Harold A Sackeim
JAMA Psychiatry. 2024-06-01

Press Mentions

Why You Should Care Who Controls PsychedelicsMay 7th, 2021
Correction: COMPASS Pathways Establishes Centre of Excellence with Sheppard Pratt to Accelerate Research and Improve Patient Experience in Mental Health CareJanuary 8th, 2021
Genomind Announces Major Industry-Leading HLA-A Test Innovation on Its Comprehensive Mental Health Pharmacogenetics (PGx) Test, Increasing Utility for Tens of Thousands of Clinicians and PatientsSeptember 10th, 2020
Join now to see all